<DOC>
	<DOCNO>NCT01279473</DOCNO>
	<brief_summary>This study investigate nilotinib provide improved safety efficacy profile see patient receive Imatinib .</brief_summary>
	<brief_title>Study Evaluate Nilotinib Adult Patients With Imatinib-resistant Imatinib-intolerant Chronic Myelogenous Leukemia ( CML ) , Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia ( ALL ) ( Extension Study )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients complete CAMN107A1101 obtain Informed concent document</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Philadelphia Chromosome Positive , ph+ ALL</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( Philadelphia Chromosome Positive )</keyword>
</DOC>